ImmunityBio, Inc. Named to Deloitte 2026 North America Technology Fast 500
ImmunityBio, Inc. was recognized as one of the fastest-growing technology-driven companies in North America in the 2026 Deloitte Technology Fast 500 rankings.
Stocks · News reference
ImmunityBio stock falls as Q3 revenue misses estimates, despite positive ANKTIVA bladder cancer trial results and Israeli approval.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
ImmunityBio, Inc. was recognized as one of the fastest-growing technology-driven companies in North America in the 2026 Deloitte Technology Fast 500 rankings.
ImmunityBio released results from a national survey conducted by The Harris Poll, highlighting diagnosis trends and care barriers for military personnel with NMIBC.
ImmunityBio announced that its senior leadership team will present at the Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference in London.
ImmunityBio announced its third-quarter 2026 financial results, reporting $48.7 million in net product revenue, alongside updates on global expansion and expanded FDA approvals.